Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated October 17, 2019
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
HIV-1 Infection
Last updated October 15, 2019
Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate)
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
HIV-1 Infection
Last updated October 15, 2019
Status:
Concluded without agreement
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Atherosclerotic cardiovascular disease
Last updated October 4, 2019
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Classic Hodgkin's Lymphoma
Last updated October 4, 2019
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated October 3, 2019
Status:
Concluded without agreement
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated September 27, 2019
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Last updated September 25, 2019
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Febrile neutropenia in non-myeloid malignancies
Last updated September 23, 2019
Velphoro (sucroferric oxyhydroxide)
Status:
Concluded with an LOI
Manufacturer:
Vifor Fresenius Medical Care Renal Pharma
Indication:
Hyperphosphatemia, end-stage renal disease
Last updated September 17, 2019